



# **Nano-sized Particles as New Radioisotopes Carriers for Medical Applications**

*A Thesis submitted*

*By*

**Basma Mohamed Said Essa**

M. Sc. of Science (Chemistry), 2015  
Assistant Lecturer at Radioactive Isotopes and Generators Department,  
Hot Labs. Center - Egyptian Atomic Energy Authority (EAEA)

*For*

**The degree of PhD in science (Chemistry)**

*Supervised By*

**Prof. Dr. Maher Abd El-Aziz Mahmoud El-Hashash (D.Sc.)**

Professor of Organic Chemistry, Faculty of Science, Ain Shams University

**Prof. Dr. Ahmed Abd El-Mohty Bayoumy**

Professor of Radiochemistry, Hot Labs. Center, Egyptian Atomic Energy Authority

**Assist. Prof. Dr. Tamer Mostafa Mohamed**

Assistant Professor of Radiopharmaceutical chemistry,

Hot Labs. Center, Egyptian Atomic Energy Authority

**To  
Chemistry Department  
Faculty of Science, Ain Shams University  
For Philosophy Doctor in Organic Chemistry  
2019**



## **Approval Sheet for submission Ph.D. Thesis**

**Name of candidate:** Basma Mohamed Said Essa

**Degree:** Ph.D. in chemistry

**Thesis title:** Nano-sized Particles as New Radioisotopes Carriers for Medical Applications

**This thesis has been approved by:**

**1- Prof. Dr. Maher Abd El-Aziz Mahmoud El-Hashash (D.Sc.)**

Professor of Organic Chemistry, Faculty of Science, Ain Shams University

**2- Prof. Dr. Ahmed Abd El-Mohty Bayoumy**

Professor of Radiochemistry, Hot Labs. Center, Egyptian Atomic Energy Authority

**4- Assist. Prof. Dr. Tamer Mostafa Mohamed**

Assistant Professor of Radiopharmaceutical chemistry,

Hot Labs. Center, Egyptian Atomic Energy Authority

**Approval**

**Prof. Dr. Ibrahim H. A. Badr**

Head of Chemistry Department,  
Faculty of Science, Ain Shams University



## **Approval Sheet for submission Ph.D. Thesis**

**Name of candidate:** Basma Mohamed Said Essa

**Degree:** Ph.D. in chemistry

**Thesis title:** Nano-sized Particles as New Radioisotopes Carriers for Medical Applications

**This thesis has been approved by:**

**1- Prof. Dr. Maher Abd El-Aziz Mahmoud El-Hashash (D.Sc.)**

Professor of Organic Chemistry, Faculty of Science, Ain Shams University

**2- Prof. Dr. Ahmed Abd El-Mohty Bayoumy**

Professor of Radiochemistry, Hot Labs. Center, Egyptian Atomic Energy Authority

**3- Prof. Dr. Elsayed Husein Mostafa Eltamany**

Professor of Organic Chemistry, Faculty of Science, Suez Canal University

**4- Prof. Dr. Nahed Youssef Khair El-Din**

Professor of Organic Chemistry, National Research Center

### **Approval**

**Prof. Dr. Ibrahim H. A. Badr**

Head of Chemistry Department,  
Faculty of Science, Ain Shams University

## **ACKNOWLEDGEMENTS**

In the name of **ALLAH**, the most merciful and almighty **WHO** gave me the courage, energy and patience to complete this study.

My first and foremost gratitude goes to my supervisor, **Professor Maher Abd El-Aziz Mahmoud El-Hashash**, Prof. of organic chemistry, Faculty of Science, Ain Shams University, for his honest and friendly guidance, his extremely useful ideas and endless professional support. Thank you very much for your valuable time and immeasurable patience.

I would like to express my deep gratitude to **Prof. Ahmed Abd El-Mohty Bayoumy**, Professor of radiochemistry, Radioisotopes and Generators Department, Hot Labs. Center, Egyptian Atomic Energy Authority, for available help, continuous advices and encouragements.

Very special thanks to my PhD supervisor **Assist. Prof. Dr. Tamer Mostafa Mohamed Sakr**, Assistant professor of radiopharmaceutical chemistry, Radioisotopes and Generators Department, Hot Labs. Center, Egyptian Atomic Energy Authority. All my deepest appreciation for the invaluable guidance and support to my professor. Actually this thesis would not have been possible without his continuous advice and constant support that provided over the course of my PhD research, for which I will remain forever grateful. His enthusiasm for the exploration of new ideas in scientific research has inspired me to constantly seek to become a better researcher.

I am sincerely thankful for **Dr. Adli AbdAllah Selim** Labeled Compounds Department, Hot Labs. Center, Egyptian Atomic Energy Authority- for his great help and unlimited support and encouragement.

Finally, I really would like to thank those who helped me even with a word of support, those who really affected and still affecting my life everywhere.

*Basma M. Essa*

| <b>Content</b>                                      | <b>Page</b> |
|-----------------------------------------------------|-------------|
| <b>List of tables</b>                               | I           |
| <b>List of figures</b>                              | II          |
| <b>List of abbreviations</b>                        | VI          |
| <b>Aim of the work</b>                              | 1           |
| <b>Abstract</b>                                     | 2           |
| <b>Summary</b>                                      | 3           |
| <b>1. INTRODUCTION</b>                              | 6           |
| 1.1. Nanotechnology                                 | 6           |
| 1.1.1. Applications of nanotechnology               | 6           |
| 1.1.1.1. Medicine and healthcare                    | 6           |
| 1.1.1.2. Environment                                | 7           |
| 1.1.1.3. Energy                                     | 8           |
| 1.1.1.4. Information and communication technologies | 8           |
| 1.1.2. Types of nanoparticles                       | 8           |
| 1.1.2.1. Carbon-based nanoparticles                 | 10          |
| 1.1.2.2. Ceramic nanoparticles                      | 10          |
| 1.1.2.3. Metal nanoparticles                        | 11          |
| 1.1.2.4. Semiconductor nanoparticles                | 11          |
| 1.1.2.5. Polymeric nanoparticles                    | 11          |
| 1.1.2.6. Lipid-based nanoparticles                  | 12          |

|            | <b>Content</b>                                          | <b>Page</b> |
|------------|---------------------------------------------------------|-------------|
| 1.1.3.     | Gold nanoparticles: synthesis and applications          | 12          |
| 1.1.4.     | Synthesis of AuNPs                                      | 13          |
| 1.1.4.1.   | Gold nanospheres                                        | 14          |
| 1.1.4.2.   | Gold nanorods                                           | 16          |
| 1.1.4.3.   | Gold nanocages                                          | 17          |
| 1.1.4.4.   | Gold nanoshells                                         | 17          |
| 1.1.5.     | Applications of gold nanoparticles                      | 17          |
| 1.1.5.1.   | Electronic and opto-electronic applications             | 17          |
| 1.1.5.2.   | Catalytic applications                                  | 18          |
| 1.1.5.3.   | Decorative applications                                 | 18          |
| 1.1.5.4.   | Contrast enhancement in electron and optical microscopy | 18          |
| 1.1.5.5.   | Pollutant removal                                       | 18          |
| 1.1.5.6.   | Medical applications                                    | 19          |
| 1.1.5.6.1. | Drug delivery                                           | 19          |
| 1.1.5.6.2. | Hyperthermal therapy                                    | 20          |
| 1.1.5.6.3. | Radio-theranosis                                        | 20          |
| 1.1.5.6.4. | Biomedical diagnostics                                  | 21          |
| 1.2.       | Radioactivity, radioisotopes and nuclear medicine       | 21          |
| 1.2.1.     | Radioactivity                                           | 21          |
| 1.2.2.     | Radioisotopes and nuclear medicine                      | 22          |
| 1.2.2.1.   | Characteristics of diagnostically radioisotopes         | 26          |

|            | <b>Content</b>                                                               | <b>Page</b> |
|------------|------------------------------------------------------------------------------|-------------|
| 1.2.2.2.   | Characteristics of radioisotopes administered internally for therapeutic use | 26          |
| 1.2.2.3.   | Some radioisotopes that used for diagnostic nuclear medicine                 | 27          |
| 1.2.3.     | Technetium-99m                                                               | 28          |
| 1.2.3.1.   | Chemistry of technetium                                                      | 28          |
| 1.2.3.2.   | Labeling with technetium-99m                                                 | 32          |
| 1.2.3.2.1. | Labeling methods with $^{99m}\text{Tc}$                                      | 33          |
| 1.2.4.     | Radiopharmaceuticals                                                         | 35          |
| 1.3.       | Nanotechnology and Cancer                                                    | 43          |
| 1.3.1.     | Advantages in using gold nanoparticles                                       | 45          |
| 1.3.1.1.   | Size and shape tunability                                                    | 45          |
| 1.3.1.2.   | Biocompatibility                                                             | 45          |
| 1.3.1.3.   | Easy detection by using various analytical methods                           | 47          |
| 1.3.1.3.1. | Ultraviolet-visible spectroscopy                                             | 47          |
| 1.3.1.3.2. | Transmission electron microscopy                                             | 48          |
| 1.3.1.4.   | Easy surface modification                                                    | 48          |
|            | <b>2. RESULTS AND DISCUSSION</b>                                             | 51          |
| 2.1.       | Gallic gold nanoparticles (gallic-GNPs)                                      | 51          |
| 2.1.1.     | Synthesis and characterization of gallic-GNPs                                | 51          |
| 2.1.2.     | <i>In-vitro</i> cytotoxicity study of gallic-GNPs                            | 54          |
| 2.1.3.     | Radiolabeling of gallic-GNPs                                                 | 54          |

|          | <b>Content</b>                                            | <b>Page</b> |
|----------|-----------------------------------------------------------|-------------|
| 2.1.3.1. | Effect of reducing agent amounts                          | 55          |
| 2.1.3.2. | Effect of pH of the reaction mixture                      | 56          |
| 2.1.3.3. | Effect of gallic-GNPs solution amount                     | 57          |
| 2.1.3.4. | Effect of reaction time and <i>in-vitro</i> stability     | 58          |
| 2.1.4.   | Recharacterization of gallic-GNPs                         | 58          |
| 2.1.5.   | Physiological <i>in-vitro</i> stability of gallic-GNPs    | 59          |
| 2.1.6.   | Biodistribution studies of <sup>99m</sup> Tc-gallic-GNPs  | 59          |
| 2.1.7.   | Conclusion                                                | 65          |
| 2.2.     | Citrate gold nanoparticles (citrate-GNPs)                 | 66          |
| 2.2.1.   | Synthesis and characterization of citrate-GNPs            | 66          |
| 2.2.2.   | <i>In-vitro</i> cytotoxicity study of citrate-GNPs        | 68          |
| 2.2.3.   | Radiolabeling of citrate-GNPs                             | 69          |
| 2.2.3.1. | Effect of reducing agent amounts                          | 70          |
| 2.2.3.2. | Effect of pH of the reaction mixture                      | 71          |
| 2.2.3.3. | Effect of citrate-GNPs solution amount                    | 72          |
| 2.2.3.4. | Effect of reaction time and <i>in-vitro</i> stability     | 73          |
| 2.2.4.   | Recharacterization of citrate-GNPs                        | 73          |
| 2.2.5.   | Physiological <i>in-vitro</i> stability of citrate-GNPs   | 74          |
| 2.2.6.   | Biodistribution studies of <sup>99m</sup> Tc-citrate-GNPs | 74          |
| 2.2.7.   | Conclusion                                                | 79          |
|          | <b>3. EXPERIMENTAL</b>                                    | <b>80</b>   |
| 3.1.     | Chemicals                                                 | 80          |

|           | <b>Content</b>                                                                             | <b>Page</b> |
|-----------|--------------------------------------------------------------------------------------------|-------------|
| 3.2.      | Equipments and tools                                                                       | 81          |
| 3.3.      | Radioactive material                                                                       | 81          |
| 3.4.      | Animals                                                                                    | 82          |
| 3.5.      | Methods                                                                                    | 82          |
| 3.5.1.    | Preparation of stock solution of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$                 | 82          |
| 3.5.2.    | Radiochemical determination                                                                | 82          |
| 3.5.3.    | Tumor induction in mice                                                                    | 84          |
| 3.5.4.    | Gallic acid gold nanoparticles (gallic-GNPs)                                               | 84          |
| 3.5.4.1.  | Synthesis and characterization of gold nanoparticles capped with gallic acid (gallic-GNPs) | 85          |
| 3.5.4.2.  | <i>In-vitro</i> cytotoxicity study of gallic-GNPs                                          | 85          |
| 3.5.4.3.  | Labeling of gallic-GNPs with technetium-99m                                                | 85          |
| 3.5.4.4.  | Physiological <i>in-vitro</i> stability study of gallic-GNPs                               | 86          |
| 3.5.4.5.  | Biodistribution studies of $^{99\text{m}}\text{Tc}$ -gallic-GNPs                           | 86          |
| 3.5.5.    | Citrate gold nanoparticles (citrate-GNPs)                                                  | 87          |
| 3.5.5.1.  | Synthesis and characterization of citrate gold nanoparticles (citrate-GNPs)                | 87          |
| 3.5.5.2.. | <i>In-vitro</i> cytotoxicity study of citrate-GNPs                                         | 88          |
| 3.5.5.3.  | Complexation of citrate-GNPs with technetium-99m                                           | 88          |
| 3.5.5.4.  | <i>In-vitro</i> stability study of citrate-GNPs in saline and serum                        | 88          |
| 3.5.5.5.  | Biodistribution studies of $^{99\text{m}}\text{Tc}$ -citrate-GNPs                          | 88          |

| <b>Content</b>        | <b>Page</b> |
|-----------------------|-------------|
| <b>REFERENCES</b>     | 89          |
| <b>Arabic summary</b> | i           |

## **List of Tables**

| <b>Table no.</b> | <b>Table title</b>                                                                        | <b>Page</b> |
|------------------|-------------------------------------------------------------------------------------------|-------------|
| Table 1          | Comparison of gold in bulk and gold in nanoparticles form                                 | 12          |
| Table 2          | Some radionuclide that used in nuclear medicine                                           | 22          |
| Table 3          | Some $^{99m}\text{Tc}$ -radiopharmaceuticals for imaging and functional studies of organs | 37          |
| Table 4          | Summary of selected cytotoxicity for gold nanoparticles                                   | 46          |

## **List of Figures**

| <b>Figure no.</b> | <b>Figure title</b>                                                                                              | <b>page</b> |
|-------------------|------------------------------------------------------------------------------------------------------------------|-------------|
| Figure 1          | Nanoscale comparison of gold nanoparticle (GNPs) with other biological materials                                 | 9           |
| Figure 2          | Generation and decay of $^{99m}\text{Tc}$ and $^{99}\text{Tc}$                                                   | 29          |
| Figure 3          | Typical radionuclide generator system                                                                            | 30          |
| Figure 4          | Plot of logarithm of $^{99}\text{Mo}$ and $^{99m}\text{Tc}$ activities versus time showing transient equilibrium | 31          |
| Figure 5          | The strategy for labeling of proteins with metal ions using bifunctional chelating agent                         | 35          |
| Figure 6          | Passive versus active targeting                                                                                  | 45          |
| Figure 7          | Absorption spectra obtained from the UV-Vis Spectroscopy for GNPs with different sizes                           | 48          |
| Figure 8          | Some physicochemical properties of GNPs                                                                          | 49          |
| Figure 9          | The size distribution histogram of gallic-GNPs                                                                   | 52          |

| <b>Figure no.</b> | <b>Figure title</b>                                                                                                 | <b>page</b> |
|-------------------|---------------------------------------------------------------------------------------------------------------------|-------------|
| Figure 10         | Zeta potential distribution of gallic-GNPs                                                                          | 53          |
| Figure 11         | TEM image of gallic-GNPs                                                                                            | 53          |
| Figure 12         | Inhibitory cytotoxic activity against normal human lung fibroblast cells in different concentrations of gallic-GNPs | 54          |
| Figure 13         | Radiochemical yield of $^{99m}\text{Tc}$ -gallic-GNPs as a function of reducing agent amount                        | 55          |
| Figure 14         | Radiochemical yield of $^{99m}\text{Tc}$ -gallic-GNPs as a function of pH.                                          | 56          |
| Figure 15         | Radiochemical yield of $^{99m}\text{Tc}$ -gallic-GNPs as a function of substrate amount                             | 57          |
| Figure 16         | Radiochemical yield of $^{99m}\text{Tc}$ -gallic-GNPs as a function of time                                         | 58          |
| Figure 17         | Stability of $^{99m}\text{Tc}$ -gallic-GNPs in human serum / saline at 37 °C followed in time                       | 59          |

| <b>Figure no.</b> | <b>Figure title</b>                                                                                                                                | <b>page</b> |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Figure 18         | Biodistribution of $^{99m}\text{Tc}$ -gallic-GNPs at different time intervals post injection in normal Albino mice                                 | 60          |
| Figure 19         | Biodistribution of $^{99m}\text{Tc}$ -gallic-GNPs at different time intervals post intravenous (I.V.) injection in solid tumor bearing Albino mice | 62          |
| Figure 20         | T/NT ratio of $^{99m}\text{Tc}$ -gallic-GNPs at different time intervals post intravenous (I.V.) Injection in solid tumor bearing Albino mice      | 63          |
| Figure 21         | Biodistribution of $^{99m}\text{Tc}$ -gallic-GNPs at different time intervals post intra tumor (I.T.) injection in solid tumor bearing Albino mice | 64          |
| Figure 22         | The size distribution histogram of citrate-GNPs                                                                                                    | 67          |
| Figure 23         | TEM image of citrate-GNPs                                                                                                                          | 67          |
| Figure 24         | Zeta potential distribution of citrate-GNPs                                                                                                        | 68          |

| <b>Figure no.</b> | <b>Figure title</b>                                                                                                  | <b>page</b> |
|-------------------|----------------------------------------------------------------------------------------------------------------------|-------------|
| Figure 25         | Inhibitory cytotoxic activity against normal human lung fibroblast cells in different concentrations of citrate-GNPs | 69          |
| Figure 26         | Radiochemical yield of $^{99m}\text{Tc}$ -citrate-GNPs as a function of reducing agent amount                        | 70          |
| Figure 27         | Radiochemical yield of $^{99m}\text{Tc}$ -citrate-GNPs as a function of pH                                           | 71          |
| Figure 28         | Radiochemical yield of $^{99m}\text{Tc}$ -citrate-GNPs as a function of substrate amount                             | 72          |
| Figure 29         | Radiochemical yield of $^{99m}\text{Tc}$ -citrate-GNPs as a function of reaction time                                | 73          |
| Figure 30         | Stability of $^{99m}\text{Tc}$ -citrate-GNPs in human serum / saline at 37 °C followed in time                       | 74          |
| Figure 31         | Biodistribution of $^{99m}\text{Tc}$ -citrate-GNPs at different time intervals post injection in normal Albino mice  | 75          |